Mucosal immunity and tolerance: Relevance to vaccine development

Immunological Reviews

Volumn 170, Issue , 1999, Pages 197-222

  Czerkinsky, Cecil ^a   Anjuere, Fabienne ^a   McGhee, Jerry R ^b   George Chandy, Annie ^a,c   Holmgren, Jan ^c   Kieny, Marie Poule ^a   Fujiyashi, Kohtaro ^b   Mestecky, Jiri F ^b   Pierrefite Carle, Valérie ^a   Rask, Carola ^c   Sun, Jia Bin ^c  

^a INSERM   (France)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT;

ALLERGIC REACTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; HOST RESISTANCE; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE; LYMPHOID CELL; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; UROTHELIUM; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOTHERAPY; INFLAMMATION; MALE; T-LYMPHOCYTES, CYTOTOXIC; VACCINES; VACCINES, DNA;

EID: 0032850897     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01339.x     Document Type: Review

References (265)

1. 1. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T-cell reactivity. Eur J Immunol 1984;14:350-356.
2. 2. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992;89:6901-6905.
3. 3. Alley CD, Mestecky J. The mucosal immune system. In: Birdand G, Calvert JE, eds. B lymphocytes in human disease. Oxford: Oxford University Press; 1988. p. 222-254.
4. 4. Allansmith MR, McClellan BH, Butterworth M, Maloney JR. The development of immunoglobulin levels in man. J Pediatr 1968;72:276-290.
5. 5. Mellander L, Carlsson B, Hanson LA. Appearance of secretory IgM and IgA antibodies to Escherichia coli in saliva during early infancy and childhood. J Pediatr 1984;104:564-568.
6. 6. Brandtzaeg P. The role of J chain and secretory component in receptor-mediated glandular and hepatic transport of immunoglobulins in man. Scand J Immunol 1989;22:111-146.
7. 7. Mestecky J, Lue C, Russell MW. Selective transport of IgA: cellular and molecular aspects. Gastroenterol Clin North Amer 1991;20:441-471.
8. 8. Guy-Grand D, Griscelli C, Vassalli P. The mouse gut T lymphocyte, a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host conditions. J Exp Med 1978;148:1661-1667.
9. 9. Davies MD, Parrott DM. The early appearance of specific cytotoxic T cells in murine gut mucosa. Clin Exp Immunol 1980;42:273-279
10. 10. MacDermott RP, Franklin GO, Jenkins KM, Kodner IJ, Nash GS, Weinrieb IJ. Human intestinal mononuclear cells. I. Investigation of antibody-dependent, lectin-induced and spontonaeous cell-mediated cytotoxic capabilities. Gastroenterology 1980;78:47-56.
11. 11. Davies MD, Parrott DM. Cytotoxic T cells in small intestine, epithelial, lamina propria and lung lymphocytes. Immunology 1981;44:367-371.
12. 12. Tagliabue A, Luini W, Soldateschi D, Boraschi D. Natural killer activity of gut mucosal lymphoid cells in mice. Eur J Immunol 1981;11:919-922.
13. 13. Nauss KM, Pavlina TM, Kumar V, Newberne PM. Functional characteristics of lymphocytes isolated from the rat large intestine. Response to T-cell mitogen and natural killer cell activity. Gastroenterology 1984;86:468-475.
14. 14. Ernst PB, Befus AD, Bienenstock J. Leukocytes in the intestinal epithelium: An unusual immunologic compartment. Immunol Today 1985;6:50-55.
15. 15. Smyth MJ, Trapani JA. The relative role of lymphocyte granule exocytosis versus death-receptor-mediated cytotoxicity in viral pathophysiology. J Virol 1998;72:1-9.
16. 16. London SD, Rubin DH, Cebra JJ. Gut mucosal immunization with reovirus serotype I/L stimulates virus-specific cytotoxic T cell precursors as well as IgA memory cells in Peyer's patches. J Exp Med 1987;165:830-847.
17. 17. Offit PA, Cunningham SL, Dudzik KI. Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection. J Virol 1991;65:1318-1324.
18. 18. London SD, Cebra-Thomas JA, Rubin DH, Cebra JJ. CD8 lymphocyte subpopulations in Peyer's patches induced by reovirus serotype 1 infection. J Immunol 1990;144:3187-3194.
19. 19. George A, Kost SI, Witzleben CL, Cebra JJ, Rubin DH. Reovirus-induced liver disease in severe combined immunodeficient (SCID) mice. A model for the study of viral infection, pathogenesis, and clearance. J Exp Med 1990;171:929-934.
20. 20. Cuff CF, Cebra CK, Rubin DH, Cebra JJ. Developmental relationship between cytotoxic α β T-cell-receptor-positive intraepithelial lymphocytes and Peyer's patch lymphocytes. Eur J Immunol 1993;23:333-1339.
21. 21. Issekutz TB. The response of gut-associated T lymphocytes to intestinal viral immunization. J Immunol 1984;133:2955-2960.
22. 22. Buzoni-Gatel, D, Lepage, AC, Dimier-Poisson, IH, Bout, DT, Kasper LH. Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasma gondi. J Immunol 1997;158:5883-5889
23. 23. Offit PA, Dudzik KI. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. J Virol 1990;64:6325-6328.
24. + T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice. J Virol 1991;65:5928-5932.
25. 25. Franco MA Greenberg HB. Role of B cells and cytotoxic T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995;69:7800-7806.
26. + T-cell immunity to murine rotavirus in the absence of perforin, fas and γ interferon. J Virol 1997;71:479-486.
27. 27. Burns JW, Siadat-Pajouh M, Krishaney AA, Greenberg HB. Protective effect of rotavirus VP6 specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996;272:104-107.
28. 28. Belyakov IM, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic. T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Aad Sci USA 1998;95:1709-1714.
29. 29. Anderson MJ, Pattison JR, Cureton RJ, Argent S, Heath RB. The role of host responses in the recovery of mice from Sendai virus infection. J Gen Virol 1980;46:5052-5060.
30. 30. Johnson RA, Prince GA, Suffin SC, Horswood RL, Chanock RM. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect Immun 1982;37:369-373.
31. 31. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992;175:1143-1145.
32. 32. Crowe JE Jr. Host responses to respiratory virus infection and immunization. Curr Top Microbiol Immunol 1999;17:191-214.
33. + T cells. J Immunol 1990;144:3980-3986.
34. + T cells. J Exp Med 1991;174:875-880.
35. + T cells. J Exp Med 1990;172:1225-1231.
36. 36. Muñoz JL, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/G mice: Clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol 1991;65:4494-4497.
37. 37. Nicholas JA, Rubino KL, Levely ME, Meyer AL, Collins PL. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication. Virology 1991;182:664-672.
38. 38. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-1033.
39. 39. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151:2032-2040.
40. 40. Miller CJ. Mucosal transmission of simian immunodeficiency virus. Curr Top Microbiol Immunol 1994;188:107-122.
41. 41. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 1995;155:5855-5860.
42. mac239. J Virol 1997;71:1911-1921.
43. 43. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185:293-303.
44. 44. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
45. 45. Weinberg AD, English M, Swain SL. Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. J Immunol 1990;144:1800-1807.
46. 46. Powers GD, Abbas AK, Miller RA. Frequencies of IL-2-and IL-4-secreting T cells in naive and antigen-stimulated lymphocyte populations. J Immunol 1988;140:3352-3357.
47. 47. Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990;171:979-96.
48. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
49. 49. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
50. 50. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987;236:944-947.
51. + T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285-1295.
52. + T cells in a Th2 response and in immunoglobulin E production. Science 1995;270:1845-1847.
53. + T-cell subsets in vivo. Immunol Rev 1991;123:189-207.
54. 54. Mosmann TR. The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol Rev 1988;102:5-28.
55. 55. Mosmann TR, Coffman RL. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
56. + T cells. J Allergy Clin Immunol 1994;94:1195-1202.
57. 57. Schooley KA, Coffman RL, Mossmann TR, Paul WE. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990;8:303-333.
58. 58. Esser C, Radbruch A. Immunoglobulin class switching: Molecular and cellular analysis. Annu Rev Immunol 1990;8:717-735.
59. 59. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T-lymphocyte clones. J Immunol 1988;140:4245-4252.
60. 60. Czerkinsky C, et al. Detection of human cytokine-secretirig cells in distinct anatomical compartments. Immunol Rev 1991;119:1-18.
61. 61. Hauer AC, Breese EJ, Walker-Smith JA, MacDonald TT. The frequency of cells secreting interferon γ, IL-4, IL-5 and IL-10 in the blood and duodenal mucosa of children with cow's milk hypersensitivity. Pediatr Res 1997;42:1-10.
62. 67. VanCott JL, et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol 1996;156:1504-1514.
63. 63. McGhee JR, Mestecky J, Elson CO, Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 1989;9:175-199.
64. 64. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor b cooperate to induce anti-CD40-activated naive human R cells to secrete immunoglobulin A. J Exp Med 1992;175:671-682.
65. 65. Van Vlasselaer P, Punnonen J, de Vries JE. Transforming growth factor-b directs IgA switching in human B cells. J Immunol 1992;148:2062-2067
66. 66. Murray PD, McKenzie DT, Swain SL, Kagnoff MF. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J Immunol 1987;139:2669-2674
67. 67. Coffman RL, Shrader B, Carty J, Mossman TR, Bond MW. A mouse T-cell product that preferentially enhances IgA production. Biologic characterization. J Immunol 1987;139:3685-3690
68. 68. Kiyono H, et al. Murine Peyer's patch T-cell clones: characterisation of antigen-specific helper T cells for immunoglobulin A responses. J Exp Med 1982;156:1115-1130.
69. 69. Kiyono H, et al. Isotype-specificity of helper T-cell clones: Peyer's patch Th cells preferentially collaborate with mature IgA B cells for IgA responses. J Exp Med 1984;159:798-811.
70. 70. Coffman RL, Lehman DA, Shrade B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 1989;170:1039-1044.
71. 71. Kim PH, Kagnoff MF. Transforming growth factor-β 1 is a costimulator for IgA production. J Immunol 1990;144:3411-3416.
72. 72. Chen Y, Kuchroo VK, Inobe JI, Haffler DA, Weiner HL. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
73. 73. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
74. 74. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down regulation of inflammatory cytokines and differential upregulation of TGF-β, IL 4 and PGF. expression in the brain. J Exp Med 1992;176:1355-1364.
75. 75. Craig SW, Cebra. JJ Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit. J Exp Med 1971;134:188-200.
76. 76. Weisz-Carrington P, Roux ME, McWilliams M, Philips-Quagliata JM, Lamm ME. Organ and isotype distribution of plasma cells producing specific antibody after oral immunization: evidence for a generalized secretory immune system. J Immunol 1979;123:1705-1708
77. 77. Scicchitano R, Stanisz A, Ernst PB, Bienenstock J. A common mucosal immune system revisited. In: Husband AJ, ed. Migration and homing of lymphoid cells. Boca Raton, FL: CRC Press; 1988. p. I-34.
78. 78. Nadal D, Albini B, Schlapfer E, Chen C, Brodsky L, Ogra PL. Tissue distribution of mucosal antibody-producing cells specific for respiratory syncytial virus in severe combined immune deficiency (SCID) mice engrafted with human tonsils. Clin Exp Immunol 1991;3:358-64.
79. 79. Czerkinsky C, et al. IgA antibody-producing cells in peripheral blood after antigen ingestion:evidence for a common mucosal immune system in humans. Proc Natl Acad Sci USA 1987;84:2449-2453.
80. 80. Czerkinsky C, Svennerholm AM, Quiding M, Johnsson R, Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun 1991;59:996-1001.
81. 81. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990;8:321-326.
82. 82. Quiding Järbrink M, et al. Human circulating antigen-specific B cell immunoblasts after mucosal and systemic immunizations: Differential homing commitments and cell surface differentiation markers. Eur J Tmrmmol 1995;25:322-327.
83. 83. Quiding-Järbrink M, et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric and nasal immunizations. A molecular basis for the compartmentalization of effector B-cell responses. J Clin Invest 1997;99:1281-1286.
84. 84. Pabst R. Is BALT a major component of the human lung immune system? Immunol Today 1992;13:119-122.
85. 85. Kupfer CF, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992;13:219-224.
86. 86. Hein WR. Organization of mucosal lymphoid tissue. Curr Top Microbiol Immunol 1999;236:1-14.
87. 87. Brandtzaeg P. Immune functions of human nasal mucosa and tonsils in health. In: Bienenstock J, ed. Immunology of the lung and upper respiratory tract. New York: McGraw-Hill; 1984. p. 28-95.
88. 88. Langman JM, Rowland R. The number and distribution of lymphoid follicles in the human large intestine. J Anat 1986;194:189-194.
89. 89. O'Leary AD, Swenney EC. Lympho-glandular complexes of the colon: structure and distribution. Histology 1986;10:267-283.
90. 90. Crago SS, et al. Distribution of IgA1-, IgA2-, and J chain-containing cells in humin tissues. J Immunol 1984;131:16-18.
91. 91. Forrest BD, Shearman DJC, La Brooy JT. Specific immune response in humans following rectal delivery of live typhoid vaccine. Vaccine 1990;8:209-212.
92. 92. Lehner T, Panagiotidi C, Bergmeier LA, Ping T, Brooks R, Adams SE. A comparison of the immune response following oral, vaginal, or rectal route of immunization with SIV antigens in nonhuman primates. Vaccine Res 1992;1:319-330.
93. 93. Lehner T, et al. T-and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency viral antigen by the rectal route. Proc Natl Acad Sci USA 1993;90:8638-8642.
94. 94. Haneberg B, Kendall D, Amerongen HM, Apter FM, Kraehenbuhl JP, Neutra MR. Induction of specific immunoglobulin-A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun 1994;62:15-23.
95. 95. Hopkins S, et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 1995;63:3279-3286.
96. 96. Moldoveanu Z, Russell MW, Wu HY. Huang W-Q, Compans RW, Mestecky J. Compartmentalization within the common mucosal immune system. Adv Exp Med Biol 1995;371:97-102.
97. 97. Nardelli-Haefliger D, et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996;64:5219-5224.
98. 98. Hordnes K, Tynning T, Kvam AI, Johnsson R, Haneberg B. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect Immun 1996;64:1643-1652.
99. 99. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1996;65:1387-1394.
100. 100. Eriksson K, et al. Specific-antibody-secreting cells in the rectums and genital tracts of non-human primates following vaccination. Immunol Infect Immun 1998;66:5889-5896.
101. 101. Saito H, et al. Generation of intestinal T cells from progenitors residing in gut cryptopatches. Science 1998;280:275-278
102. 102. Lubeck MD, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994;10:1443-1449.
103. 103. Quidíng-Järbrink M, Granström G, Nordström I, Holmgren J, Czerkinsky C. Induction of compartmentalized B-cell responses in human tonsils. Infect Immun 1995;63:853-857.
104. 104. Gallichan WS, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13:1589-1595
105. 105. Gallichan WS, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex glycoprotein B. J Infect Dis 1993;168:622-629.
106. 106. Pal S, Peterson EM, de la Maza LM. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun 1996;64:5341-5348.
107. 107.Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 1996;64:1272-1282.
108. 108. Di Tommaso A, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996;64:974-979.
109. 109. Staats HF, Nichols WG, Palker TJ. Systemic and vaginal antibody respones after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 1996;157:462-472.
110. 110. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997;65:2676-2684.
111. 111. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998;66:514-20.
112. 112. Hameleers DM, Stoop AE, van der Ven I, Biewenga J, van der Baan S, Sminia T Intraepithelial lymphocytes and non-lymphoid cells in the human nasal mucosa. Int Arch Allergy Appl Immunol 1989;88:17-22.
113. 113. Graeme-Cook F, Bhan AK, Harris NL. Immunohistochemical characterization of intraepithelial and subepithelial mononuclear colls of the upper airways. Am J Pathol 1993;143:1416-22.
114. 114. Kupfer CF, Hameleers DM, Bruijntjes JP, van der Ven I, Biewenga J, Sminia T. Lymphoid and non-lymphoid cells in nasal-associated lymphoid tissue (NALT) in the rat. An immuno-and enzyme-histochemical study. Cell Tissue Res 1990;259:371-377.
115. 115. van der Ven I, Sminia T. The development and structure of mouse nasal-associated lymphoid tissue: an immuno-and enzyme-histochemical study. Reg Immunol 1993;5:69-75
116. 116. Ogra PL. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N Engl J Med 1979;284:59-64.
117. 117. Edwards JN, Morris HB. Langerhans'cells and lymphocyte subsets in the female genital tract. Br J Obstet Gynaecol 1985;92:974-982.
118. 118. Hussain LA, et al. Expression and gene transcript of Fc receptors for IgG, HLA class II antigens and Langerhans cells in human cervico-vaginal epithelium. Clin Exp Immunol 1992;90:530-538.
119. 119. Olaitan A, Johnson MA, MacLean A, Poulter LW. The distribution of immunocompetent cells in the genital tract of HIV-positive women. AIDS 1996;10:759-764.
120. 120. Kutteh WH, Hatch KD, Blackwell RE, Mestecky J. Secretory immune system in the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. Obstetr Gynecol 1988;71:56-60.
121. 121. Kutteh WJ, Mestecky J. Secretory immunity in the female reproductive tract. Am J Reprod Immunol 1994;31:40-46.
122. 122. Ogra PL, Ogra SS. Local antibody response to poliovaccine in the female genital tract. J Immunol 1973;110:1307-1311.
123. 113. Wassen L, Schon K, Holmgren J, Jertborn M, Lycke N. Local intraviginal vaccination of the female genital tract. Scaud J Immunol 1986;44:408-414.
124. 124. Mestecky J, Kutteh WH, Jackson S. Mucosal immunity in the female genital tract: relevance to vaccination efforts against the human immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10: S11-S20.
125. 125. Bergman KC, Waldman RH, Tischner H, Pohl W. Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine. Int Arch Allergy Appl Immunol 1986;80:107-109.
126. 126. Bergman KC, Waldman RH. Oral immunization with influenza virus: Experimental and clinical studies. Curr Top Microbiol Immunol 1989;146:83-89.
127. 117. Moldoveanu Z, Clements, ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995;3:1006-1012.
128. 128. Ohlsson-Wilhelm BM, Duncan JD, Mestecky J, Compans RW. Mucosal immunization against influenza virus using bioadhesive polymers. Proceedings, Options for the Control of Influenza III. 1998. (In press).
129. 129. Gizurarson G, Jonsdottir VM, Heron I. Intranasal administration of diptheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. Vaccine 1995;13:617-621.
130. 130. Michalek SM, Eldridge JH, Curtiss III R, Rosenthal KL. Antigen delivery systems: new approaches to mucosal immunization. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Handbook of mucosal immunology. San Diego: Academic Press; 1994. p. 373-390.
131. 131. Gould-Fogerite S, et al. Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization. AIDS Res Human Retroviruses 1994;10:599-5103.
132. 132. Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM. Vaccine containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989;251:191-202.
133. 133. Duncan JD, Gilley RM, Schafer DP, Moldoveanu Z, Mestecky J. Poly (lactide-coglycolide) microencapsulation of vaccines for mucosal immunization. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal vaccines. San Diego: Academic Press; 1996. p. 159-173.
134. 134. Mestecky J, Eldridge JH. Targeting and controlled release of antigens for the effective induction of secretory antibody responses. Curr Opin Immunol 1991;3:492-495.
135. 135. Mestecky J, et al. Current options for vaccine delivery systems by mucosal routes. J Controlled Release 1997;48:243-257.
136. 136. McKenzie SJ, Halsey JF. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 1984;133:1818-1824.
137. 137. De Aizpurtia HJ, Russell-Jones GJ. Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J Exp Med 1988;167:440-451.
138. 138. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun 1989;57:1072-1077
139. 139. Bergquist C, Lagergard T, Lindblad M, Holmgren J. Local and systemic responses to dextran-cholera toxin B subunit conjugates. Infect Immun 1995;63:2021-2025.
140. 140. Sanchez J, Johansson S, Löwenadler B, Svennerholm A-M, Holmgren J. Recombinant cholera toxin B-subunit and gene fusion proteins for oral vaccination. Res Microbiol 1990;141:971-979.
141. 141. Dertzbaugh MT, Elson CO. Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun 1993;61:48-55.
142. 142. Sanchez J, Holmgren J. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci USA 1989;86:481-485.
143. 143. Jobling MG, Holmes RK. Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras. Infect Immun 1992;60:4915-4924.
144. 144. Hajishengallis G, Hollingshead SK, Koga T, Russell MW. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995;154:4322-4332.
145. 145. Sultan F, Jin LL, Jobling MG, Holmes RK, Stanley SL Jr. Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect Immun 1998;66:462-468.
146. 146. Moxon RE. Applications of molecular microbiology to vaccinology. Lancet 1991;350:1240-1244.
147. 147. Plotkin SA. Vaccination in the 21st century. J Infect Dis 1993;168:29-37.
148. 148. Curtiss R, Kelly SM, Hassan JO. Live oral avirulent Salmonella vaccines. Vet Microbiol 1993;37:397-405.
149. 149. Doggett TA, Brown PK. Attenuated Salmonella as vectors for oral immunization. In: Kiyono II, Ogra PL, McGhee JR, eds. Mucosal Vaccines. San Diego: Academic Press; 1996. p. 105-108.
150. 150. Chatfield S, Roberts M, Londono P, Cropley I, Douce G, Dougan G. The development of oral vaccines based on live attenuated Salmonella strains. FEMS Immunol Med Microbiol 1993;7:1-7.
151. 151. Roberts M, Chatfield, SN, Dougan G. Salmonella as carriers of heterologous antigens. In: O'Hagan DT, ed. Novel delivery systems for oral vaccines. Boca Raton, FL: CRC Press; 1994. p. 27-41.
152. 152. Schodel F, Curtiss R III. Salmonella as oral vaccine carriers. Dev Biol Stand 1995;84:245-53.
153. 153. Gonzales C, et al. Salmonella ryphi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety about immunogenicity in humans. J Infra Dis 1994;169:927-931.
154. -) vaccine expressing a major leisbmanial surface protein (gp 63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990;145:2281-2285.
155. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun 1996;64:1516-1525.
156. 156. Stover CK. Recombinant vaccine delivery systems and encoded vaccines. Curr Opin Immunol 1994;6:568-571
157. 157. Renauld-Mongénie G, et al. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc Natl Acad Sci USA 1996;93:7944-7949.
158. 158. Graham FL. Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol 1989;70:429-434.
159. 159. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185-1187.
160. 160. Graham FL, Smiley J, Russell WC, Nairn R. Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
161. 161. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998;177:1155-1161.
162. 162. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996;184:1879-1890.
163. 163. Buge SL, et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-8541
164. 164. Prevec L, Campbell JB, Christie BS, Belbeck L, Graham FL. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990;161:27-30.
165. 165. Hsu KH, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5 and 7 vectors in dogs and a chimpanzee. J Infect Dis 1992;166:769-775.
166. 166. Tacket CO, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1992;10:673-676.
167. 167. Baca-Estrada ME, Liang X, Babiuk LA, Yoo D. Induction of mucosal immunity in cotton rats to haemagglutinin-esterase glycoprotein of bovine coronavirus by recombinant adenovirus. Immunology 1995;86:134-140.
168. 168. Kagami H, et al. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of tolerance. Hum Gene Ther 1998;10:305-313.
169. 169. Brochier B, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991;354:520-522.
170. 170. Kieny MP, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984;312:163-166.
171. 171. Meitin CA, Bender BS, Small PA Jr. Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci USA 1994;91:11187-11191.
172. 172. Ramsay AJ, Kohonen-Corish M. Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 1993;23:3141-3145.
173. 173. Paoletti, E. Applications of poxvirus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-11353.
174. 174. Welter J, Taylor J, Tartaglia J, Paoletti E, Stephensen CB. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection. Vaccine 1999;17:308-318.
175. 175. Gonin P, Oualikene W, Fournier A, Eloit M. Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice. Vaccine 1996;14:1083-1087.
176. 176. Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978;41:225-234.
177. 177. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-1040.
178. 178. Morrow CD, Novak MJ, Ansardi DC, Porter DC, Moldoveanu Z. Recombinant viruses as vectors for mucosal immunity. Curr Top Microbiol Immunol 1999;236:255-273.
179. 179. Caley IJ, et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997;71:3031-3038.
180. 180. Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 1996;70:3781-3787.
181. 181. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239:389-401.
182. 182. Tang S, van Rij R, Silvera D, Andino R. Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J Virol 1997;71:7841-7850.
183. 183. Anderson MJ, Porter DC, Moldoveanu Z, Fletcher TM 3rd, McPherson S, Morrow CD. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses 1997;13:53-62.
184. 184. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
185. 185. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
186. 186. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN mediated natural killer activity. J Immunol 1992;148:4072-4076.
187. 187. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
188. 188. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
189. 189. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA 1996;93:2879-2883.
190. 190. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998;161:2428-2434.
191. 191. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligonucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998;161:3042-3049.
192. 192. Moldoveanu Z, Love-Homan L, Huang WQ, Kríeg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998;16:1216-1224.
193. 193. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482.
194. 194. Wang B, et al. Gene inoculation generates immune responses against HIV-1. Proc Natl Acad Sci USA 1993;90:4156-4160.
195. 195. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 1997;71:3138-3145.
196. 196. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D, Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997;78:1577-1580.
197. 197. Baragazzi ML, et al. Safety and immunogenidly of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. J Med Primatol 1997;26:27-33.
198. 198. McCluskie MJ, Chu Y, Xia JL, Jessee J, Gebyehu G, Davis HL. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev 1998;8:401-414.
199. 199. Okada E, et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638-3647.
200. 200. Sasaki S, et al. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type I with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 1998;66:823-826.
201. 201. Klavinskis LS, Birnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999;162:254-262.
202. 202. Jones DH, Clegg JC, Farrar GH. Oral delivery of micro-encapsulated DNA vaccines. Dev Biol Stand 1998;92:149-155.
203. 203. Chen SC, et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998;72:5757-5761.
204. 204. Darji A, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91:765-775.
205. 205. Paglia P, Medina E, Arioli I, Guzman CA Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998;92:3172-3176.
206. 206. Condon C, Watkins SC, Celluzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transaction of dendritic cells. Nat Med 1996;2:1122-1128.
207. 207. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona C. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997;186:1481-1486.
208. 208. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages. J Immunol 1998;160:5707-5718.
209. 209. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999;189:169-177.
210. 210. Mason HS, Lam DMK, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992;89:11745-11749.
211. 211. Arntzen CJ, Mason HS. Oral vaccine production in the edible tissues of transgenic plants. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. New York: Marcel Dekker; 1996. p. 263-267.
212. 212. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;3912:245-252.
213. 213. Mayordomo JI, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997;15:94-63.
214. 214. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.
215. + cytolytic T-cell responses. J Exp Med 1995;182:1663-1671.
216. 116. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J. Borrelia burgdorferi-pulsed dendritic cells induce protective immune response against tick transmitted spirochetes. Infect Immun 1997;65:3386-3390.
217. 217. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendfitit cells as a means to induce CTL. J Immunol 1997;158:3270-3276.
218. 218. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. Vaccination against chlamydial genital tract infection after immunisation with dendritic cells pulsed with nonviable chlamydiac. J Exp Med 1998;188:809-818.
219. 219. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992;56:622-647.
220. 220. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun 1988;56:1748-1753.
221. 221. Elson CO, Ealding W. Cholera toxin did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated antigen. J Immunol 1984;133:2892-2898.
222. 222. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986;2:301-308.
223. 223. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988;6:269-277.
224. 224. Xu-Amano J, et al. Helper T-cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1990;172:95-103.
225. 225. Munoz E, Zubiaga AM, Merrow M, Sauter NP, Huber BT. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J Exp Med 1992;175:131-138.
226. 226. Marinaro M, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995;155:4621-4629.
227. 227. Snider DP, Marshall, JS, Perdue MH, Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1994;153:647-657.
228. 228. Wilson AD, Bailey M, Williams NA, Stokes CR. The in vitro production of cytokines by mucosal lymphocytes immunised by oral administration of key-hole limpet hemocyanin using cholera toxin as an adjuvant. Eur J Immunol 1991;21:2333-2339.
229. 229. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an effective transmucosal carrier delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994;91:10795-10799.
230. 230. Bowen JC, Nair SK, Reddy R, Rouse BT. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 1994;81:338-342.
231. 231. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Eschirichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992;22:2277-2281.
232. 232. Takahashi I, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996;173:627-635.
233. 233. Douce G, et al. Mutants of Escherichia foli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Prot Natl Acad Sci USA 1995;92:1644-1648.
234. 234. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995;63:1617-1623.
235. 235. Yamamoto S, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997;94:5267-5272.
236. 236. Yamamoto S, et al. Mutants in the ADP-ribosytransferase cleft of cholera toxin lack diarrhocagenicity but retain adjuvanticity. J Exp Med 1997;185:1203-1210.
237. 237. Challacombe SJ, Tomasi TB Jr. Systemic tolerance and secretory immunity after oral immunization. J Exp Med 1980;152:1459-1472.
238. 238. Karpus WJ, Lukacs NW. The role of chemokines in oral tolerance: abrogation of nonresponsiveness by treatment with anti-MCP-1. Ann N Y Acad Sci 1996;778:133-142.
239. 239. Strobel S, Mowat AM, Drummond HE, Pickering MG, Ferguson A. Immunological responses to fed protein antigens in mice. II Oral tolerance for CMI is due to activation of cyclophosphamide-sensitive cells by gut-processed antigen. Immunology 1983;49:451-456.
240. 240. Bruce MG, Strobel, S, Hanson DG, Ferguson A. Transferable tolerance for cell-mediated immunity after feeding is prevented by radiation damage and restored by immune reconstitution. Clin Exp Immunol 1987;70:611-618.
241. 241. Mayer L, So LP, Yio XY, Small G. Antigen trafficking in the intestine. Ann N Y Acad Sci 1996;778:28-35.
242. 242. Kaiserlian D. The intestinal epithelial cell: a non conventional type of antigen-presenting cell. In: Auricchio S, Ferguson A, Troncone R, eds. Mucosal immunity and the gut epithelium: interactions in health and disease. Basel: Karger; 1995. p. 32-39.
243. 243. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens J Exp Med 1992;175:131-138.
244. 244. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992;258:1156-1159.
245. 245. MacPherson GG, Liu LM. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr Top Microbiol Immunol 1999;236:34-53.
246. 246. Stumbles PA, et al. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 1998;188:2019-2031.
247. 247. Steptoe RJ, Thomson AW. Dendritic cells and tolerance induction. Clin Exp Immunol 1996;105:397-402.
248. 248. Vincy JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 1998;160:5815-5825.
249. 249. Khoury SJ, Lider O, Al-Sabbagh A, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol 1982;131:302-310.
250. 250. Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatry 1982;138:341-344.
251. 251. Wortman F. Oral hyposensitization of children with pollinosis or house dust asthma. Allergol Immunopathol 1977;5:15-26.
252. 252. Hoyne GF, O'Hehir RE, DC Wraith, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783-1788.
253. 253. Hanson DG, Vaz NM, Rawlings LA, Lynch JM. Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization. J Immunol 1979;122:2261-2266.
254. 254. Staines NA, Harper N, Ward FJ, Thompson HSG, Bansal S. Arthritis: animal models of oral tolerance. Ann N Y Acad Sci 1996;778:297-305.
255. 255. Czerkinsky C, et al. Cholera toxin B snbunit as transmucosal carrier-delivery and immunomodulating system for induction of anti-infections and anti-pathological immunity. Ann N Y Acad Sci 1996;778:185-193.
256. 256. Sun JB, Rask C, Ollson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephatomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996;93:7196-7201.
257. 257. Tarkowski A, Sun JB, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum (In press).
258. 258. Bergerot I, et al. A cholera toxoid-insulin conjugate as oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610-4614.
259. 259. Ma D, Mellon J, Niederkorn JY. Conditions affecting enhanced corneal allograft survival by oral immunization. Invest Ophthalmol Vis Sci 1998;39:1835-1846.
260. 260. Tamura S, Hatori E, Tsuruhara T, Aizawa C, Kurata T. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 1997;15:225-229.
261. 261. Julia V, Rassoulzadegan M, Glaichenhaus. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996;274-421-423.
262. 261. McSorley SJ, Rask C, Pichot R, Julia V, Czerkinsky C, Glaichenhaus, N. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur J Immunol 1998;28:44-430.
263. 263. Sun JB, et al. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoide conjugate vaccine epokes antiparasitic and antipathological immunity in mice. J Immunol 1999;163:1045-1052.
264. 264. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998;16:934-938.
265. 265. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5:387-391.